Medium urgency

Outsourcing Facility Fee Rates for Fiscal Year 2027

Detected July 30, 2026 · in Pharmacy & Controlled Substances

FDA announces FY 2027 fee rates for outsourcing facilities that compound human drugs: establishment fee $18,714, reinspection fee $4,679.

Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Outsourcing facilities (compounding pharmacies that elect to register with FDA) that compound human drugs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Fees are due for FY 2027 starting October 1, 2026. Specific payment deadline not stated; check FDA guidance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FY 2027 establishment fee set at $18,714 (up from $17,803 in FY 2026) and reinspection fee at $4,679 (up from $4,451).

Who it affects

Outsourcing facilities (compounding pharmacies that elect to register with FDA) that compound human drugs.

What you must do

Pay the applicable establishment fee by the due date (typically October 1, 2026, or upon registration).

Deadline

Fees are due for FY 2027 starting October 1, 2026. Specific payment deadline not stated; check FDA guidance.

Source: https://www.federalregister.gov/documents/2026/07/30/2026-15342/outsourcing-facility-fee-rates-for-fiscal-year-2027

Never miss a change like this again

Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmacy & Controlled Substances